Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares representing 10,287,000 ordinary shares, which included 1,341,782 ADSs sold pursuant to a full exercise of the underwriters’ over-allotment option. The ADSs are listed on the Nasdaq Global Select Market under the symbol “ABCM” and Abcam’s ordinary shares are admitted to trading on the AIM market of the London Stock Exchange under the symbol “ABC.”

Headquartered in Cambridge, United Kingdom, Abcam is a global life science company focused on identifying, developing and distributing high-quality reagents and tools for its customers at the forefront of life science research. Its products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery.

The Davis Polk corporate team included partner Marcel Fausten and associates Carrie Guo and Dylan H. Lojac. Partner Simon Witty and associate Aya Aboulatta provided English law advice. The intellectual property and technology transactions team included partner David R. Bauer and associates Yifu Chen. Partners Mario J. Verdolini and Jonathan Cooklin, and counsel Dominic Foulkes provided U.S. and English tax advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post